Metabolisches Syndrom – Warum es uns so schwerfällt abzunehmen

Metabolic syndrome is characterised by the metabolic sequelae of obesity and is associated with an increased risk of diabetes mellitus and cardiovascular disease. The term was coined in the 1980s and describes in particular the onset of fat and glucose metabolism disorders, as well as arterial hypertension as a result of an increase in abdominal fat tissue. Due to the continuous weight gain worldwide, the prevalence of metabolic syndrome is increasing; at the same time, the number of people with diabetes is rising. The basis of treatment for metabolic syndrome is weight reduction; this reverses its components and reduces the risk of serious sequelae. The most effective, but also the most invasive treatment is bariatric surgery. A number of drugs, such as appetite suppressants, pancreatic lipase inhibitors and glucagon-like peptide (GLP-1) analogues, have already been approved; options with other targets (e.g. combined glucose-dependent insulinotropic polypeptide [GIP]/GLP‑1 agonists) can be expected in the future. © 2021, Springer Medizin Verlag GmbH, ein Teil von Springer Nature.